---
layout: default
title: Nadolol
parent: Model Prediction Only (L5)
nav_order: 950
evidence_level: L5
indication_count: 5
---

# Nadolol
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **5** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Nadolol: From Beta-Blocker Therapy to Malignant Hypertensive Renal Disease

## One-Sentence Summary

Nadolol is an oral non-selective beta-blocker marketed in the United States as generic tablets. The provided records do not list its approved indications.
The TxGNN model predicts it may be effective for **malignant hypertensive renal disease**, but there are **0 clinical trials** and **no drug-specific publications** supporting this prediction.
It is a model-only signal (Evidence Level L5).

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not stated in the provided US license records |
| Predicted New Indication | Malignant hypertensive renal disease |
| TxGNN Prediction Score | 99.59% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (all listed licenses are ANDAs, i.e. generics) |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in the record. Based on known pharmacology, nadolol is a non-selective beta-blocker that lowers blood pressure and suppresses renin release. That is biologically plausible in renin-driven hypertensive kidney injury, and it is the only mechanistic support for the prediction.

There are also reasons for caution:
- Malignant hypertension is a hypertensive emergency, usually managed with IV agents. An oral long-acting beta-blocker is not a natural fit.
- The original indication field is empty, so the relationship between the old and new indications could not be cross-checked.
- The identical scores for related predictions (malignant renovascular hypertension, and the two pulmonary hypertension entries) suggest a shared graph neighborhood rather than independent evidence.

**Other predicted indications** (all L5, all Hold):

| Rank | Predicted Indication | Score | Comment |
|---|---|---|---|
| 2 | Malignant renovascular hypertension | 99.59% | Renin link is theoretical. RAAS inhibitors are the usual choice, and there is no evidence for nadolol. |
| 3 | Pulmonary hypertension owing to lung disease and/or hypoxia | 99.53% | The 20 retrieved papers are general hypoxia biology, not nadolol studies. |
| 4 | Pulmonary hypertension with unclear multifactorial mechanism | 99.53% | Beta-blockers are generally not recommended in PH because they can reduce cardiac output and right ventricular function. |
| 5 | Braddock syndrome | 99.43% | Ultra-rare disorder. The score likely comes from graph proximity via the PH phenotype. |

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

No literature directly studying nadolol or beta-blockers in malignant hypertensive renal disease was found. Literature was retrieved only for the rank 3 indication (pulmonary hypertension owing to lung disease and/or hypoxia). Those 20 papers appear to be keyword matches on "hypoxia", and none studies nadolol. There are no RCTs; the examples below are the reviews and basic-research papers among them.

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [33862277](https://pubmed.ncbi.nlm.nih.gov/33862277/) | 2021 | Review | Ageing Res Rev | Hypoxia and brain aging. Not drug-specific. |
| [34618295](https://pubmed.ncbi.nlm.nih.gov/34618295/) | 2022 | Review | Metab Brain Dis | Clinical evidence and molecular mechanisms of hypoxia-induced cognitive impairment. Not drug-specific. |
| [34535359](https://pubmed.ncbi.nlm.nih.gov/34535359/) | 2021 | Review | Clin Oncol | Therapeutic modification of tumour hypoxia. Not related to nadolol. |
| [11172576](https://pubmed.ncbi.nlm.nih.gov/11172576/) | 2000 | Review | Respir Care Clin N Am | Basic mechanisms of hypoxemia. Background physiology only. |
| [37328448](https://pubmed.ncbi.nlm.nih.gov/37328448/) | 2023 | Preclinical | Adv Sci (Weinheim) | NAT10/HIF-1α glycolysis loop in gastric cancer. Unrelated. |

---

## US Market Information

The records list 20 licenses in total; 5 are shown. All are oral tablets, and none includes approved-indication text.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| ANDA212856 | NADOLOL (VGYAAN Pharmaceuticals LLC) | Tablet | Not listed in the record |
| ANDA210955 | Nadolol (Unichem Pharmaceuticals (USA), Inc.) | Tablet | Not listed in the record |
| ANDA203455 | Nadolol (BluePoint Laboratories) | Tablet | Not listed in the record |
| ANDA207761 | Nadolol (Zydus Lifesciences Limited) | Tablet | Not listed in the record |
| ANDA203455 | Nadolol (Cipla USA Inc.) | Tablet | Not listed in the record |

---

## Safety Considerations

Please refer to the package insert for safety information. Package-insert warnings and contraindications were not captured in the data, and no drug-drug interaction records were found.

Class-level concerns raised in the prediction review:
- **Bronchospasm:** non-selective beta-blockers such as nadolol can provoke bronchospasm and are generally avoided in significant chronic lung disease, which is the typical context for the hypoxia-related PH group.
- **Pulmonary hypertension:** beta-blockers can reduce cardiac output and right ventricular function.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
All five predictions are model-only (L5) with no clinical trials and no drug-specific literature. The clinical fit for the top prediction is weak, and the safety profile is a concern for the pulmonary hypertension predictions. The package-insert safety review is also incomplete, which blocks progression to safety screening.

**To proceed, the following is needed:**
- FDA package insert warnings and contraindications (download and parse the label)
- Mechanism of action data from DrugBank (DB01203)
- Original approved indications, to assess the link to the predicted indication
- A targeted literature search for nadolol or beta-blockers in malignant hypertension and renin-mediated hypertensive nephropathy
- Clinical justification for an oral long-acting beta-blocker in a hypertensive emergency setting
- Route compatibility assessment (currently pending)

*This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

